Impact of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia
10.3760/cma.j.issn.0529-567x.2018.06.004
- VernacularTitle:化疗对妊娠滋养细胞肿瘤患者卵巢功能与生命质量的影响
- Author:
Wei XUE
1
;
Junjun YANG
;
Jun ZHAO
;
Tong REN
;
Fengzhi FENG
;
Xirun WAN
;
Yang XIANG
Author Information
1. 100730,中国医学科学院北京协和医院妇产科
- Keywords:
Gestational trophoblastic disease;
Antineoplastic combined chemotherapy protocols;
Ovarian reserve;
Quality of life;
Surveys and questionnaires
- From:
Chinese Journal of Obstetrics and Gynecology
2018;53(6):377-383
- CountryChina
- Language:Chinese
-
Abstract:
Objective Using a questionnaire to evaluate different regimens of chemotherapy on ovarian function and quality of life of patients with gestational trophoblastic neoplasia (GTN).Methods At least 6 months after completion of chemotherapy,200 patients with GTN treated in Peking Union Medical College Hospital from January 2010 to June 2017 were randomly selected to fill up the questionnaire.The questionnaire items were included the patient's menstrual cycles,sexual life,gestational issues and common health.The patients were divided into 3 groups by chemotherapy regimens:actinomycin D (Act-D) group,floxuridine + Act-D + vincristine (FAV) or floxuridine + Act-D + etoposide + vincristine (FAEV) group (FAV-FAEV group),and etoposide + methotrexate + Act-D (EMA)/vincristine + cyclophosphamide (CO) or EMA/ etoposide + cisplatin (EP) group (EMA/CO-EMA/EP group).Chi-square test was used with a significance level of P-value less than 0.05.Results One hundred and seventy-three (86.5％,173/200) of the patients completed the questionnaire.Forty three point two percent (43.2％,19/44) in the EMA/CO-EMA/EP group had a normal menstrual cycle,which were significantly lower than those of Act-D group (84.6％,22/26) and FAV-FAEV group (71.2％,37/52;all P＜O.05).Amenorrhea rate was also significantly higher in EMA/CO-EMA/EP group (25.0％,11/44) than in Act-D group(0) and FAV-FAEV group (17.3％,9/52;all P＜0.05).The sexual life parameters were comparable among 3 groups.Ten out of thirty-two patients conceived after chemotherapy,2 had miscarriages and 8 had full-term delivery of healthy babies.The common health and labor capacity were significantly decreased after chemotherapy (all P＜0.05).Conclusions EMA/CO or EMA/EP regimen have a worse impact on ovarian function than Act-D and FAV or FAEV regimen.Gynecologic oncologist should be concerned about the ovarian function and quality of life of GTN patients.
